Abstract: A backlight adjustment method and a backlight adjustment system are provided. The backlight adjustment method includes a compensation phase. The compensation phase includes: controlling a light source to respectively emit light having a plurality of first illuminations; detecting a plurality of backlight parameters of a display device under the light having the plurality of first illuminations, and calculating a brightness compensation coefficient of the display device according to the plurality of backlight parameters; and adjusting a backlight coefficient of the display device according to the brightness compensation coefficient, so as to compensate for backlight brightness of the display device.

Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Abstract: An example operation may include one or more of submitting, by a blockchain client, a transaction proposal to a blockchain network, endorsing, by one or more endorser nodes or peers, the transaction proposal, endorsing comprising updating an in-process world state list, providing one or more composite endorsements, each comprising a base result and a forecasted result corresponding to the transaction proposal, submitting an endorsed transaction in response to the one or more composite endorsements, validating, by a committer node or peer, the endorsed transaction, committing the endorsed transaction to the blockchain network, and removing the committed transaction from the in-process world state list.

Abstract: What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a mixture of a triglyceride of ricinoleic acid and a gelling agent, in a formulation with loteprednol, latanoprost, celecoxib, triamcinolone, or betamethasone and, optionally, a second corticosteroid, analgesic, or anti-inflammatory agent.

Abstract: What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a triglyceride of ricinoleic acid, a gelling agent, bupivacaine and, optionally, a corticosteroid, an analgesic, or an anti-inflammatory agent.

Abstract: Smart television signal source-based method for displaying floating menu and smart television, comprising: calling floating menu to any position on current page when receiving signal source forced to be broadcast; floating menu acquiring signal source channel, and, according to system file configuration, acquiring configuration entries requiring display by current smart television model, before displaying on current page; configuration entries automatically undergoing dynamic sorting according to current system status.

Abstract: What is disclosed is a semi-solid controlled release pharmaceutical composition containing biocompatible and bioerodible semi-solid lipid matrix incorporating local anesthetics agents to form a semi-solid solution, a method of using the pharmaceutical composition to treat, and a method of making the pharmaceutical composition.

Abstract: The present application discloses a vehicle control wearable apparatus. The vehicle control wearable apparatus includes a detector configured to detect an intoxicating substance intake level of a potential driver of a vehicle; a vehicle operation state controller coupled to the detector and configured to receive the intoxicating substance intake level from the detector; and a first data transceiver coupled to the vehicle operation state controller. The vehicle operation state controller is configured to conduct a comparison between the intoxicating substance intake level and a first threshold level, and control the first data transceiver to send a blocking signal based on a first result of the comparison at a first time point. The blocking signal controlling the vehicle in a blocked state thereby prevents the potential driver from driving the vehicle.

Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Abstract: A backlight adjustment method and a backlight adjustment system are provided. The backlight adjustment method includes a compensation phase. The compensation phase includes: controlling a light source to respectively emit light having a plurality of first illuminations; detecting a plurality of backlight parameters of a display device under the light having the plurality of first illuminations, and calculating a brightness compensation coefficient of the display device according to the plurality of backlight parameters; and adjusting a backlight coefficient of the display device according to the brightness compensation coefficient, so as to compensate for backlight brightness of the display device.

Abstract: What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a triglyceride of ricinoleic acid, a gelling agent, bupivacaine and, optionally, a corticosteroid, an analgesic, or an anti-inflammatory agent.

Abstract: What is described is a semi-solid controlled release composition comprising a semi-solid lipid and bupivacaine in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.

Abstract: A computer implemented method for selecting breakpoints for cross-layer debugging is provided. The method includes receiving code comprising a plurality of layers, and executing a static analysis of the code to obtain a use-definition (UD) chain, alias information, and a parameter mapping for each of the plurality of layers. The method also includes determining a statement of the code that produces one of an error and a failure, and generating a table comprising a plurality of fields including a working statement field, watching variable field, and a watching function field. The method includes adding the determined statement to the working statement field and performing a cross-layer analysis includes identifying at least one used variable and its associated alias as watching variables from the added working statement, searching the code based on the watching variable field. The method includes generating cross-layer suspect code points based on the cross-layer analysis.

Abstract: The present invention relates to stable liquid formulations of ketoprofen, amitriptyline, and oxymetazoline.

Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Abstract: Flexible utilization of capacity to provide computing services mediated by a service broker. The service broker receives a request from a first party for assistance with a service workload as well as an indication from a second party of a willingness to provide service. The service broker matches the parties with each other based at least in part on the capacity of the second party to service the service workload of the first party, manages offloading of the service workload from first party to the second party, and manages billing of a workload provider (such as the first party or the first party's customer) for the offloading engagement.

Abstract: A computer implemented method for selecting breakpoints for cross-layer debugging is provided. The method includes receiving code comprising a plurality of layers, and executing a static analysis of the code to obtain a use-definition (UD) chain, alias information, and a parameter mapping for each of the plurality of layers. The method also includes determining a statement of the code that produces one of an error and a failure, and generating a table comprising a plurality of fields including a working statement field, watching variable field, and a watching function field. The method includes adding the determined statement to the working statement field and performing a cross-layer analysis includes identifying at least one used variable and its associated alias as watching variables from the added working statement, searching the code based on the watching variable field. The method includes generating cross-layer suspect code points based on the cross-layer analysis.

Abstract: The present application discloses a vehicle control wearable apparatus. The vehicle control wearable apparatus includes a detector configured to detect an intoxicating substance intake level of a potential driver of a vehicle; a vehicle operation state controller coupled to the detector and configured to receive the intoxicating substance intake level from the detector; and a first data transceiver coupled to the vehicle operation state controller. The vehicle operation state controller is configured to conduct a comparison between the intoxicating substance intake level and a first threshold level, and control the first data transceiver to send a blocking signal based on a first result of the comparison at a first time point. The blocking signal controlling the vehicle in a blocked state thereby prevents the potential driver from driving the vehicle.

Abstract: What is described is a semi-solid controlled release composition comprising a semi-solid lipid and bupivacaine in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.

Abstract: The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.